Immunoprecise Cash Flow from Operations

IPA
 Stock
  

USD 3.94  0.01  0.25%   

Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
As of July 6, 2022, Net Cash Flow from Operations is expected to decline to about (744.5 K). In addition to that, Free Cash Flow is expected to decline to about (2.5 M).

Immunoprecise Cash Flow from Operations Analysis

Immunoprecise Antibodies' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
 2019 2020 2021 2022 (projected)
Interest Expense537 K517 K594.55 K596.14 K
Gross Profit8.03 M11.54 M13.27 M11.78 M
Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
More About Cash Flow from Operations | All Equity Analysis

Current Immunoprecise Antibodies Cash Flow from Operations

    
  (8.87 M)  
Most of Immunoprecise Antibodies' fundamental indicators, such as Cash Flow from Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunoprecise Cash Flow from Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for Immunoprecise Antibodies is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Cash Flow from Operations. Since Immunoprecise Antibodies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunoprecise Antibodies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunoprecise Antibodies' interrelated accounts and indicators.

Immunoprecise Cash Flow from Operations Historical Pattern

Today, most investors in Immunoprecise Antibodies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunoprecise Antibodies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash flow from operations growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunoprecise Antibodies cash flow from operations as a starting point in their analysis.
 Immunoprecise Antibodies Cash Flow from Operations 
Share
      Timeline 
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Compare to competition

Immunoprecise Net Cash Flow from Operations

Net Cash Flow from Operations

(744,474)

Immunoprecise Antibodies Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (690,000)
In accordance with the recently published financial statements, Immunoprecise Antibodies has (8.87 Million) in Cash Flow from Operations. This is 101.68% lower than that of the Healthcare sector and 114.19% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.91% higher than that of the company.

Did you try this?

Run Equity Search Now

   

Equity Search

Search for actively traded equities including funds and ETFs from over 30 global markets
All  Next Launch Module

Immunoprecise Fundamentals

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Net Cash Flow from Operations-690 K-744.5 K
Free Cash Flow-2.3 M-2.5 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Immunoprecise Antibodies Investors Sentiment

The influence of Immunoprecise Antibodies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunoprecise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immunoprecise Antibodies Implied Volatility

    
  256.02  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Current Sentiment - IPA

Immunoprecise Antibodies Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunoprecise Antibodies. What is your judgment towards investing in Immunoprecise Antibodies? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
96.9 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.